Propofol is used when deep sedation, immobilization and quick emergence are required and is often used in children during magnetic resonance imaging (MRI) scans. Because the MRI scan is prolonged, a propofol infusion or repetitive small boluses are usually administered.
critically ill patients. The syndrome is characterized by severe metabolic acidosis, myocardial dysfunction, rhabdomyolysis, myoglobinuria, renal failure, hypoxia and death. The mechanism of muscle toxicity is unknown. Muscle pathology reveals necrosis of skeletal and cardiac muscle. Discontinuation of propofol with supportive therapy for myoglobinuria, metabolic acidosis, hyperkalaemia and renal failure is the mainstay of treatment [4] . The pathogenesis of propofol infusion syndrome is not fully explained and potential mechanisms include lactic acidosis, metabolic acidosis and mitochondrial toxicity. Lactic acid production is caused by low cardiac output or a regional steal syndrome due to propofol influence as a cardiodepressant, cardiac failure or septic shock.
Metabolic acidosis may be caused by impaired hepatic lactate metabolism. Supportive evidence includes the development of a fatty or enlarged liver [5] . Intermediate dihydroxylated products of propofol are thought to have mitochondrial toxicity which could cause metabolic acidosis. Furthermore, there might be an occult mitochondrial dysfunction in the subjects who developed the syndrome [5, 6] .
Muscle tissue is highly sensitive to drugs and toxins because of its high metabolic activity and multiple potential sites for foreign substances to disrupt the energy-producing pathways. Children have reduced ability to metabolize or excrete drugs and thus have increased risk for toxic myopathy [7] .
The exact incidence of toxic myopathy is unknown, but probably is often unrecognized. Early recognition of toxic myopathy is important since the likelihood of complete resolution is higher with early removal of the offending toxin. The diagnosis is based on lack of other known aetiology for the myopathy, lack of previous muscular symptoms and resolution of the symptoms after withdrawal of the suspected toxic agent. Drugs or toxins can produce mild symptoms of muscle pain and cramps, as in the patient we described, or cause a severe weakness, rhabdomyolysis, hyperkalaemia and renal failure [7] . In conclusion, this case of severe myalgia following propofol infusion might be caused by either Paediatric renal transplantation: a single centre study doi: 10.1017/S0265021506001748 EDITOR: Renal transplantation is the definitive treatment of choice for children with end-stage renal failure. Clinical outcome indices in paediatric renal transplantation remain inferior to those in adults due to the higher incidence of acute tubular necrosis and graft loss from vascular thrombosis and primary non-function [1] [2] [3] . After Institutional Research Ethics Board approval, the anaesthetic and perioperative management of 34 consecutive patients who received a renal transplant at the Hospital for Sick Children, Toronto, Canada between January 2001 and August 2003 were reviewed. Results are expressed as mean Ϯ SD.
There were 20 male and 14 female patients, with a mean age at transplant of 11.2 Ϯ 5.3 yr (range: 2-18 yr) and weight of 36.1 Ϯ 15.2 kg (range: 13-60 kg). There were five patients who weighed less than 15 kg. The aetiology of renal failure is listed in Table 1 . Twenty-nine patients were receiving dialysis (17 haemodialysis, 12 peritoneal dialysis) at the time of transplantation. Five patients did not receive dialysis prior to renal transplantation as these patients were receiving donor organs from family members. Livedonor grafts were used in 56% of patients, 35% received a cadaveric adult kidney and 9% received a cadaveric paediatric kidney.
All patients were intubated and ventilated after induction of anaesthesia with intravenous agents: propofol (29 patients) or sodium thiopental (5 patients). Crystalloids, 5% albumin or red blood cell concentrate were given at 53 Ϯ 24 mL kg Ϫ1 (range: 22-109 mL kg Ϫ1 ) to maintain intravascular volume and achieve a central venous pressure (CVP) of 14 Ϯ 2 mmHg (range: 11-19 mmHg) prior to release of renal vessel cross clamps. Ten patients (29%) received packed cells perioperatively to achieve a haemoglobin of 8-10 g dL Ϫ1 . Mannitol (0.5-1.0 g kg Ϫ1 ) and furosemide (1 mg kg Ϫ1 ) were administered intravenously prior to 
